Imagine if AI could understand an
individual’s health based on their data

Vibhor has a breadth of experience in life sciences through his work in industry and academia over the last two decades. Prior to Pangaea, Vibhor started and built the European business for Quantum Secure, which was an enterprise software solutions provider headquartered in Silicon Valley and was successfully acquired by a global corporation in 2015. Following his work at Quantum Secure, Vibhor served as Senior Vice President of Commercial Strategy and Sales at Seven Bridges Genomics, which was founded at Harvard and provided a cloud based bioinformatics platform. Vibhor has also worked as a management and technology consultant for Deloitte. Vibhor’s academic career focused on conducting molecular biology studies and building bioinformatics tools and machine learning models with epigenetic, genomic, transcriptomic and clinical trial data in the context of oncology and infectious diseases. Vibhor has access to an extensive global network in the Life sciences industry and is regularly invited to speak at international conferences, government funded programs and investment summits.

Professor Yike Guo assumed office as the Vice-President (Research and Development) of HKBU on 1 January 2020. Professor Guo is also Professor of Computing Science in the Department of Computing at Imperial College London (2002 – now, on leave since 2020 January). Before joining HKBU, he was the founding Director of the Data Science Institute at Imperial College since 2014, which is one of the six Imperial College Global Challenge Institutes. He is a Fellow of the Royal Academy of Engineering (FREng), Member of Academia Europaea (MAE), Fellow of British Computer Society (FBCS). Professor Guo has published over 250 articles, papers and reports. Projects he has contributed to have been internationally recognized, including winning the “Most Innovative Data Intensive Application Award” at the Supercomputing 2002 conference for Discovery Net, the Bio-IT World “Best Practices Award” for U-BIOPRED in 2014 and the “Best Open Source Software Award” from ACM SIGMM in 2017.

Jingqing is the Head of AI at Pangaea Data Limited. He received his BEng degree in Computer Science and Technology from Tsinghua University, 2016, and MRes degree with distinction in Computing from Imperial College London, 2017. He was awarded National Scholarship of China (top 1%) in 2015. He is the founder and main contributor of some popular deep learning tools including TensorLayer 2.0 and PEGASUS. His projects receive over 8,000 stars on GitHub. Jingqing is also the final year PhD student at Imperial College London with research interest in clinical natural language processing and was a research intern at Google Brain prior to Pangaea.

Dr. Musen is Professor of Biomedical Informatics at Stanford University, where he is Director of the Stanford Center for Biomedical Informatics Research. Dr. Musen conducts research related to open science, data stewardship, intelligent systems, and biomedical decision support. His group developed Protégé, the world’s most widely used technology for building and managing terminologies and ontologies. He is principal investigator of the National Center for Biomedical Ontology, one of the original National Centers for Biomedical Computing created by the U.S. National Institutes of Heath (NIH). Dr. Musen chaired the Health Informatics and Modeling Topic Advisory Group for the World Health Organization’s revision of the International Classification of Diseases (ICD-11) and he currently directs the WHO Collaborating Center for Classification, Terminology, and Standards at Stanford University. Early in his career, Dr. Musen received the Young Investigator Award for Research in Medical Knowledge Systems from the American Association of Medical Systems and Informatics and a Young Investigator Award from the National Science Foundation. In 2006, he was recipient of the Donald A. B. Lindberg Award for Innovation in Informatics from the American Medical Informatics Association.

Rick is a 28-year veteran of the pharmaceutical industry, having held senior positions in Clinical Development at Merck & Co. and AstraZeneca. His career has included leading cardiovascular drug development at Merck, and leadership roles in the U.S. Business, Global Medical Sciences, and New Opportunities at AstraZeneca. In 2014 he became a Managing Director in QuintilesIMS (now IQVIA) Consulting Services and then a Senior Vice-President in IQVIA Design & Delivery Innovation, leading the Strategic Drug Development business unit. This unit supports biopharma companies to design integrated development, regulatory, and commercial strategies for their assets, as well as due diligence activities. Rick now is the Managing Director of Pharma Design Solutions, Ltd., his own consultancy practice, supporting senior biopharmaceutical executives with their corporate and organizational aspirations, as well as technology companies interested in improving R&D productivity in the pharmaceutical industry.